ARCH Venture Fund IX Exits Gossamer Bio Position

TL;DR

**ARCH Venture Fund IX is out of Gossamer Bio, watch for potential stock impact.**

AI Summary

ARCH Venture Fund IX, L.P. and its affiliates, including ARCH Venture Partners IX, L.P. and ARCH Venture Partners IX, LLC, have filed an SC 13G/A indicating they are exiting their position in Gossamer Bio, Inc. This amendment, filed on February 9, 2024, marks a significant change from their previous holdings, with the 'Date of Event Which Requires Filing' being July 24, 2023. This matters to investors because a major institutional investor is no longer holding shares, which could signal a loss of confidence or a strategic portfolio reallocation.

Why It Matters

This filing signals that a significant institutional investor, ARCH Venture Fund IX, has sold off its entire stake in Gossamer Bio, Inc., which could be interpreted negatively by the market.

Risk Assessment

Risk Level: medium — The exit of a major institutional investor like ARCH Venture Fund IX could indicate a lack of future growth prospects or concerns about the company's direction, potentially leading to downward pressure on the stock.

Analyst Insight

A smart investor would investigate the reasons behind ARCH Venture Fund IX's exit from Gossamer Bio, Inc. and consider if this signals underlying issues before making any investment decisions.

Key Players & Entities

• ARCH Venture Fund IX, L.P. (company) — reporting person exiting position
• Gossamer Bio, Inc. (company) — subject company whose shares were held
• ARCH VENTURE PARTNERS IX OVERAGE, L.P. (company) — group member
• ARCH VENTURE PARTNERS IX, L.P. (company) — group member
• ARCH VENTURE PARTNERS IX, LLC (company) — group member
• CLINTON BYBEE (person) — group member
• KEITH CRANDELL (person) — group member
• ROBERT NELSEN (person) — group member
• July 24, 2023 (date) — date of event requiring filing
• February 9, 2024 (date) — filing date

Forward-Looking Statements

• Gossamer Bio's stock price may experience downward pressure in the short term. (Gossamer Bio, Inc.) — medium confidence, target: 3 months
• Other institutional investors might re-evaluate their positions in Gossamer Bio. (Gossamer Bio, Inc.) — low confidence, target: 6 months

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• arch-sch13g_18793.htm (SC 13G/A) — 80KB
• 0001072613-24-000116.txt ( ) — 82KB

From the Filing

SC 13G/A 1 arch-sch13g_18793.htm ARCH VENTURE FUND IX, L.P. - GOSSAMER BIO -- SCH 13G/A(#1-EXIT) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 – Exit Filing)* Gossamer Bio, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 38341P102 (CUSIP Number) July 24, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 38341P102 13G Page 2 of 7 Pages Item 1(a). Name of Issuer Gossamer Bio, Inc. (the “Issuer”). Item 1(b). Address of Issuer's Principal Executive Offices 3013 Science Park Road, San Diego, CA 92121 Item 2(a). Name of Person Filing ARCH Venture Fund IX, L.P. (“AVF IX”); ARCH Venture Partners IX, L.P. (“AVP IX LP”); ARCH Venture Partners IX, LLC (“AVP IX LLC”); ARCH Venture Fund IX Overage, L.P. (“AVF IX Overage”) ; ARCH Venture Partners IX Overage, L.P. (“AVF IX Overage GP”) (collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”) and Clinton Bybee (“Bybee”) (collectively, the “Managing Directors” and individually, each a “Managing Director”). The Reporting Entities and the Managing Directors collectively are referred to as the Reporting Persons”. Item 2(b). Address of Principal Business Office or, if none, Residence 8755 W. Higgins Road, Suite 1025, Chicago, IL 60631 Item 2(c). Citizenship Each of AVF IX, AVF IX LP, AVF IX Overage and AVP IX Overage GP, are limited partnerships organized under the laws of the State of Delaware. AVP IX LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen. Item 2(d). Title of Class of Securities Common stock, par value $0.0001 per share. Item 2(e). CUSIP Number 38341P102 Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: Not Applicable. CUSIP No. 38341P102 13G Page 3 of 7 Pages Item 4. Ownership Not Applicable. Item 5. Ownership of Five Percent or Less of a Class Each of the Reporting Persons has ceased to beneficially own five percent (5%) or more of the Issuer’s outstanding Common Stock. Item 6. Ownership of More than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company Not Applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certifications Not Applicable. CUSIP No. 38341P102 13G Page 4 of 7 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 9, 2024 ARCH VENTURE FUND IX, L.P. By: ARCH Venture Partners IX, L.P. its General Partner By: ARCH Venture Partners IX, LLC its General Partner By: * Keith Crandell Managing Director ARCH VENTURE PARTNERS IX, L.P. By: ARCH Venture Partners IX, LLC its General Partner By: * Keith Crandell Managing Director ARCH VENTURE FUND IX OVERAGE, L.P. By: ARCH Venture Partners IX Overage, L.P. its General Partner By: ARCH Venture Partners IX, LLC its General Partner By: * Keith Crandell Managing Director ARCH VENTURE PARTNERS IX OVERAGE, L.P. By: ARCH Venture Partners IX, LLC its General Partner By: * Keith Crandell Managing Director ARCH VENTURE PARTNERS IX, LLC By: * Keith Crandell Managing Director CUSIP No. 38341P102 13G Page 5 of 7 Pages * Keith Crandell * Robert Nelsen * Clinton Bybee * By: /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact * This Amendment No. 1 to Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney file